A population pharmacodynamic Markov mixed-effects model for determining remimazolam-induced sedation when
Jie Zhou1, Laura Curd1, Lauren R L Lohmer1
1Nuventra Pharma Sciences, Durham, North Carolina, USA.
Abstract:
The clinical effects of remimazolam (an investigational, ultra-short acting benzodiazepine being studied in procedural sedation) were measured using the Modified Observer's Assessment of Awareness/Sedation Scale (MOAA/S). The objective of this analysis was to develop a population pharmacokinetic/pharmacodynamic model to describe remimazolam-induced sedation with fentanyl over time in procedural sedation. MOAA/S from 10 clinical phase I-III trials were pooled for analysis, where data were collected after administration of placebo or remimazolam with or without concomitant fentanyl. A Markov model described transition states for 35,356 MOAA/S-time observations from 1071 subjects. Effect-compartment models of remimazolam and fentanyl linked plasma concentrations to the Markov model, and drug effects were described using a synergistic maximum effect (Emax ) model. Simulations were performed to identify the optimal remimazolam-fentanyl combination doses in procedural sedation. Fentanyl showed synergistic effects with remimazolam in sedation. Increasing age was related to longer recovery from sedation. Patients with body mass index greater than 25 kg/m2 had ~30% higher rates of distribution from plasma to the effect site (keo), indicating a slightly faster onset of sedation. Simulations showed that remimazolam 5 mg was more appropriate than 4 or 6 mg when administered with fentanyl 50 μg. The model and simulations support that a combination of remimazolam 5 mg with fentanyl 50 μg is an appropriate dosing regimen and the dose of remimazolam does not need to be changed in elderly patients, but some elderly patients may have a longer duration of sedation.
Insights
Remimazolam combined with fentanyl provides effective procedural sedation. A population model suggests 5mg remimazolam and 50μg fentanyl is optimal, with age influencing recovery time.
Area of Science:
- Pharmacology
- Clinical Trials
- Pharmacokinetics/Pharmacodynamics
Background:
- Remimazolam is an investigational ultra-short-acting benzodiazepine for procedural sedation.
- Assessing sedation depth is crucial for patient safety during procedures.
Purpose of the Study:
- To develop a population pharmacokinetic/pharmacodynamic (PK/PD) model for remimazolam-induced sedation.
- To evaluate the synergistic effects of fentanyl with remimazolam.
- To identify optimal dosing regimens for procedural sedation.
Main Methods:
- Pooled data from 10 Phase I-III clinical trials (35,356 observations, 1071 subjects).
- Utilized a Markov model for sedation state transitions.
- Incorporated effect-compartment models for remimazolam and fentanyl PK/PD.
- Employed a synergistic Emax model for drug effects.
Main Results:
- Fentanyl demonstrated synergistic effects with remimazolam on sedation.
- Older age correlated with prolonged recovery from sedation.
- Higher BMI (>25 kg/m²) was associated with faster sedation onset (increased keo).
- Simulations indicated 5mg remimazolam with 50μg fentanyl as an optimal combination.
Conclusions:
- The developed PK/PD model accurately describes remimazolam-fentanyl sedation.
- A combination of 5mg remimazolam and 50μg fentanyl is recommended for procedural sedation.
- Remimazolam dosage adjustments are not necessary for elderly patients, though sedation duration may increase.
More Related Videos
08:49Assessing Changes in Volatile General Anesthetic Sensitivity of Mice after Local or Systemic Pharmacological Intervention
Published on: October 16, 2013
07:54Drug-Induced Sleep Endoscopy DISE with Target Controlled Infusion TCI and Bispectral Analysis in Obstructive Sleep Apnea
Published on: December 6, 2016
Related Concept Videos
01:17Sedatives and Hypnotics Drugs: Miscellaneous Agents
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...
01:24Parenteral Anesthetics: Overview
01:23Sedatives and Hypnotics: Overview
Sedative-hypnotics are categorized into barbiturates, benzodiazepines (BZDs), and non-benzodiazepines or Z-drugs. These drugs work by suppressing central nervous system activity, and this suppression is dose-dependent. Older sedative medications, like barbiturates, follow a linear curve in...
01:22Stages of General Anesthesia
01:01Dosage Regimens: Partial Pharmacokinetic Parameters
01:19Sedatives and Hypnotics Drugs: Benzodiazepines
Benzodiazepines work by enhancing the effects of the inhibitory neurotransmitter GABA. They bind to the GABAA receptor, increasing its affinity for GABA, which opens chloride...